#USA #Phoenix #Cyrex Laboratories #BiomeBurden #immune sensitivity

Cyrex Laboratories Unveils BiomeBurden™

Cyrex Laboratories, a prominent clinical lab specializing in functional immunology and autoimmunity, recently announced an exciting new product: BiomeBurden™. This innovative testing system is designed to evaluate immune sensitivity against various microbial triggers, including specific types of yeast and mold. As the understanding of gut health deepens, this cutting-edge solution reflects an evolving perspective on immunity and chronic illness management.

Overview of BiomeBurden™ Testing

The BiomeBurden™ test comprises a comprehensive three-panel system that assesses an individual’s immune response to an array of pathogens. The first panel, known as MycoBiomeBurden, screens for six significant Candida species, including various virulence factors such as germ tube and candidalysin alongside several food-related molds.

The second component, termed MicroBiomeBurden, broadens the scope to include multiple cross-reactive tissue antigens and a selection of both aerobic and anaerobic bacteria. Completing the package is BiomeBurden Complete, which integrates findings from the previous two panels while providing additional insights into T-cell functionality and lymphocyte activity within the immune system, specifically focusing on the Th1, Th2, and Th17 cells. This rich dataset allows clinicians to uncover intricate details about how a patient’s body reacts to various antigens and potential triggers.

The Importance of Gut Microbiome

In the last few years, awareness has surged regarding the gut microbiome's crucial role in maintaining a healthy immune balance. Dysbiosis—an imbalance in the gut bacteria, particularly through the overgrowth of specific fungi like Candida—has been linked to numerous chronic conditions, including ulcerative colitis, liver autoimmune disorders, and various syndromes. By identifying these microbial imbalances, healthcare providers have an opportunity to target the underlying issues, enabling more proactive and beneficial health outcomes for patients.

Mark McDonough, CEO of Cyrex Laboratories, articulated the importance of BiomeBurden™ by stating, "This launch signifies a critical shift in how individuals can comprehend and manage their health. By emphasizing immune activation instead of merely identifying antigens, we hope to reveal deeper insights into the body’s responses." The objective here is clear: to shift the paradigm from merely treating symptoms to discovering root causes, paving the way for preventive healthcare and individualized strategies.

A Holistic Approach to Immune Response

The Chief Scientific Advisor at Cyrex, Dr. Aristo Vojdani, emphasized the uniqueness of the BiomeBurden™ blood test. Unlike traditional stool or swab tests that primarily center on gut health, BiomeBurden™ delivers a comprehensive overview of the immune response across multiple bodily systems. This holistic approach allows healthcare professionals to gain better insights into how the mycobiome and microbiome interact with autoimmune conditions and overall immune health.

Accessing This Innovative Testing

For those interested in this advanced testing solution, Cyrex's product line, including the BiomeBurden™ series, is exclusively accessible through orders placed by licensed healthcare professionals. As the company continues to deliver pioneering innovations, they invite healthcare practitioners to explore the various arrays within the Cyrex System to learn more about their functions and benefits. For further information, visit Join Cyrex.

With BiomeBurden™, Cyrex Laboratories empowers patients and healthcare providers with the tools to better understand and navigate the dynamic world of microbial health, fostering a more informed, preventive approach to wellbeing.